UK Markets closed
  • FTSE 100

    7,466.07
    -88.24 (-1.17%)
     
  • FTSE 250

    21,643.30
    -211.27 (-0.97%)
     
  • AIM

    1,082.51
    -4.13 (-0.38%)
     
  • GBP/EUR

    1.2014
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.3401
    +0.0019 (+0.1447%)
     
  • BTC-GBP

    28,161.09
    +840.63 (+3.08%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • S&P 500

    4,431.85
    +105.34 (+2.43%)
     
  • DOW

    34,725.47
    +564.69 (+1.65%)
     
  • CRUDE OIL

    87.29
    +0.68 (+0.79%)
     
  • GOLD FUTURES

    1,792.30
    -2.70 (-0.15%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • HANG SENG

    23,550.08
    -256.92 (-1.08%)
     
  • DAX

    15,318.95
    -205.32 (-1.32%)
     
  • CAC 40

    6,965.88
    -57.92 (-0.82%)
     

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference

·1-min read

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference

Marseille, France, January 6, 2022ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre d’Epenoux, will present a corporate overview on Monday, January 10th at 7:30 am Eastern Time/13:30 Central European Time during the 40th Annual J. P. Morgan Healthcare Conference being held virtually from January 10 - 13, 2022.

***

About IMCHECK THERAPEUTICS

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.

For further information on ImCheck: http://www.imchecktherapeutics.com and @ImCheckThx

Press contacts

US and EU
Trophic Communications
Gretchen Schweitzer
+49 (0) 172 861 8540
imcheck@trophic.eu

France
ATCG PARTNERS
Céline Voisin
+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39
imcheck@atcg-partners.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting